US Corporate Distress Financial Stress SEC Filings — April 22, 2026

22-04-2026

Amneal Pharmaceuticals announced a definitive agreement to acquire Kashiv BioSciences for $375 million cash and $375 million equity at closing, plus up to $350 million in milestone payments and royalties, to build a fully integrated global biosimilars platform targeting over $300 billion in biologics LOE opportunities, expecting more than 12 commercial biosimilars by 2030. Preliminary Q1 2026 results showed consolidated net revenue of $723 million (+4% YoY), with Specialty net revenue up 23% to $133 million, Affordable Medicines up 2% to $423 million, but AvKARE down 4% to $166 million; gross margin expanded 750 bps to 44.3%. The company raised FY2026 standalone guidance, including Adjusted EBITDA to $740 million-$770 million (from $720 million-$760 million) and Adjusted diluted EPS to $0.95-$1.05.

• ·Transaction expected to close in H2 2026, subject to shareholder and regulatory approvals.
• ·Expected $400M-$500M in financial synergies from acquisition.
• ·CREXONT® contributed $21M, Brekiya® $5M, RYTARY® $44M, UNITHROID® $36M in Q1 Specialty revenue.
• ·FY2026 guidance assumes ~330M weighted-average diluted shares; operating cash flow raised to $350M-$400M.

22-04-2026

HIVE Digital Technologies Ltd. announced the upsizing and pricing of a private offering of US$100 million aggregate principal amount of 0% exchangeable senior notes due 2031 (upsized from US$75 million), issued by its subsidiary HIVE Bermuda 2026 Ltd., with an option for initial purchasers to buy an additional US$15 million. The notes carry an initial exchange price of approximately US$2.57 per common share (17.5% premium to the April 16, 2026 Nasdaq closing price) and net proceeds of approximately US$95 million (or US$109.5 million if option exercised) will fund general corporate purposes, capital investments including GPUs, and data center development. The company also entered capped call transactions with a cap price of US$4.92 per share (125% premium to closing price), funded partly by US$17.2 million in cash on hand.

• ·Notes mature on April 15, 2031; exchangeable starting under certain conditions prior to January 15, 2031.
• ·Expected closing date: April 21, 2026, subject to customary conditions.
• ·Holders can require repurchase on April 15, 2029, or upon fundamental change.
• ·Issuer may redeem prior to April 20, 2029 only on tax events; after April 20, 2029 if share price >=130% of exchange price.
• ·Common shares expected to cease trading on TSXV and commence on TSX around April 30, 2026; TSX listing conditional by June 30, 2026.
• ·Capped call transactions to reduce dilution upon exchange, subject to anti-dilution adjustments.

22-04-2026

National Healthcare Corporation (NHC) entered a Purchase and Sale Agreement to acquire real estate of 32 skilled nursing facilities and 3 independent living facilities from National Health Investors, Inc. (NHI) for $560 million, expected to close in Q3 2026 and be accretive to earnings and cash flow. NHC currently leases and operates most of these facilities and will continue doing so post-acquisition, except for four Florida skilled nursing facilities which will be leased to a third-party operator. The transaction is subject to customary closing conditions including HSR antitrust review, with risks of termination or delays noted.

• ·Facilities located in Alabama, Florida, Kentucky, Missouri, South Carolina, Tennessee, and Virginia
• ·Subject to Hart-Scott-Rodino Antitrust waiting period
• ·NHC operates under prior Master Agreement to Lease with NHI

22-04-2026

Churchill Capital Corp IX and Plus Automation, Inc. (PlusAI) mutually terminated their Agreement and Plan of Merger and Reorganization, originally entered on June 5, 2025, effective April 20, 2026, citing market conditions. The termination involves AL Merger Sub I, Inc. and AL Merger Sub II, LLC as subsidiaries of Churchill. No financial terms or impacts from the termination are disclosed.

• ·Filing Date: April 22, 2026
• ·Registrant CIK: 0002086744
• ·IRS Employer Identification No.: 93-2913093
• ·Principal Executive Offices: 3315 Scott Boulevard, Suite 300, Santa Clara, California 95054

22-04-2026

FreeCast, Inc. entered into a Renewal Revolving Convertible Promissory Note on April 20, 2026, with Nextelligence, Inc. (controlled by CEO William A. Mobley, Jr.), renewing a prior note up to $5M principal, with $5,114,052 outstanding as of the effective date. Nextelligence converted $1,714,052 of principal into 484,354 shares of Class A common stock, reducing the outstanding principal to $3,400,000 at 12% interest, due June 30, 2027; however, the note remains a significant related-party obligation with potential default rate of 18%. The shares were issued in an unregistered transaction exempt under Sections 4(a)(2) and 3(a)(9) of the Securities Act.

• ·Note interest rate: 12% per annum; default rate: 18% per annum.
• ·Maturity date: June 30, 2027.
• ·Conversion price: closing price of Class A common stock on Nasdaq on most recent trading day prior to conversion notice.
• ·Company has right to prepay with 5 days prior notice.
• ·Shares issued exempt under Sections 4(a)(2) and 3(a)(9) of Securities Act; Nextelligence is accredited investor.

22-04-2026

Spruce Biosciences, Inc. (NASDAQ: SPRB) announced a proposed underwritten public offering of shares of its common stock or pre-funded warrants, with joint book-running managers Leerink Partners, Guggenheim Securities, and Oppenheimer & Co., and co-managers Jones and Craig-Hallum. The company expects to grant underwriters a 30-day option to purchase up to 15% additional shares at the public offering price, less discounts. The offering is subject to market conditions, with no assurance on completion, size, or terms, and is made pursuant to a shelf registration on Form S-3 effective November 26, 2025.

• ·Shelf registration on Form S-3 filed October 29, 2025, declared effective November 26, 2025.
• ·Announcement date: April 20, 2026.
• ·SEC filing date: April 22, 2026.

22-04-2026

Brand Engagement Network, Inc. (BEN) announced a strategic investment of up to $1,000,000 in Accelevate Solutions, including an initial $250,000 payment, via a binding term sheet to advance AI in fleet operations and establish in-vehicle engagement channels. The collaboration integrates BEN's AI with Accelevate's fleet infrastructure, targeting the commercial fleet market with billions in tech spend, supported by BEN's newly granted U.S. Patent No. 12,581,163. No declines or flat metrics reported.

• ·U.S. Patent No. 12,581,163 titled 'Systems and Methods for Delivering User-Specific Messages' granted to BEN.
• ·Accelevate platform available on Geotab Marketplace and integrates with MyRadar.
• ·Sources: Geotab State of Commercial Transportation Report (2024); International Energy Agency (IEA) Global EV Outlook.

22-04-2026

Datadog, Inc. converted from a Delaware corporation to a Nevada corporation pursuant to NRS Chapters 78 and 92A, adopting new Articles of Incorporation as Exhibit 3.1 to the 8-K filing. The authorized shares total 2,330,000,000, comprising 2,000,000,000 shares of Class A Common Stock, 310,000,000 shares of Class B Common Stock, and 20,000,000 shares of Preferred Stock, all with a par value of $0.00001 per share. Provisions detail Class B stock rights, including transfer restrictions to preserve voting control for founders Olivier Pomel and Alexis Lê-Quôc, with no financial performance metrics reported.

• ·Board of Directors authorized to issue Preferred Stock in series via Certificate of Designation filed with Nevada Secretary of State.
• ·Class B Common Stock transfer restrictions apply to Qualified Stockholders and Permitted Transferees to maintain Voting Control.
• ·Final Conversion Date defined as 5:00 p.m. NY time on the tenth anniversary of the Effective Time or next Trading Day.
• ·Filing date: April 22, 2026

22-04-2026

Certara, Inc. (Nasdaq: CERT) announced a definitive agreement to sell its Regulatory and Medical Writing business to Veristat for consideration of up to $135 million, expected to close in Q2 2026, sharpening focus on Model-Informed Drug Development (MIDD) and Clinical Intelligence. The divested business generated $50 million in revenue and $17 million in adjusted EBITDA in 2025, employing approximately 220 people. Certara plans to update its 2026 guidance upon close and deploy proceeds for long-term value creation.

• ·Perella Weinberg Partners LP served as financial advisor and Troutman Pepper Locke LLP as legal counsel to Certara.
• ·Guggenheim Securities, LLC served as financial advisor and McDermott Will & Schulte as legal counsel to Veristat.
• ·Certara's clients span more than 2,600 biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries.

22-04-2026

Spire Inc. (NYSE: SR) announced the sale of its Mississippi natural gas distribution business, Spire Mississippi, to Delta Utilities (backed by Bernhard Capital Partners) for $75 million in cash, at a 1.4x multiple of 2025 rate base. The divested unit serves approximately 18,000 customers across 745 miles of pipelines in south-central Mississippi, representing a small portion of Spire's total ~2 million customers. Proceeds will fund infrastructure investments in Spire's remaining regulated utilities in Alabama, Missouri, and Tennessee, with closing expected in the first fiscal quarter of 2027 subject to regulatory approvals.

• ·Transaction subject to customary closing conditions, including approval by the Mississippi Public Service Commission.
• ·Spire employees directly supporting the business expected to transition to Delta Utilities.
• ·Stinson LLP acted as legal counsel to Spire.

22-04-2026

TuHURA Biosciences announced a $50 million credit facility from an affiliate of its largest stockholder, K&V Investment One LLC, providing non-dilutive funding to extend cash runway into 2028 for pipeline development, including IFx-2.0 through Phase 3 results and TBS-2025 to key efficacy milestones. The facility allows monthly draws as needed at 12% annual interest, secured by company assets, with principal due at 5-year maturity on April 21, 2031, and includes a low to mid-single digit royalty on IFx-2.0 commercial sales. No declines or flat metrics reported; forward-looking risks include potential inability to draw funds or insufficient coverage for operations.

• ·Draws available monthly on as-needed basis for clinical development and operations
• ·Interest paid monthly; principal repayment at maturity on April 21, 2031
• ·Low to mid-single digit royalty on annual commercial sales of IFx-2.0 by Company or sublicensees
• ·Merger with Kineta Inc. on June 30, 2025 acquired TBS-2025
• ·10-K for fiscal year ended December 31, 2025 filed March 31, 2026

22-04-2026

Genvor Inc entered into a securities purchase agreement effective April 16, 2026, with Evergreen Capital Management LLC for a convertible promissory note with aggregate principal up to $800,000 and warrants to purchase up to 600,000 shares of common stock, for a purchase price up to $666,668 payable in four tranches of $166,667 each. The first tranche was funded at initial closing, with remaining tranches contingent on the Company filing a Form S-1 registration statement for resale shares and receiving SEC comments. Additional exhibits include an Advisory Agreement with Brio Advisory Group LLC dated April 14, 2026.

• ·Securities Purchase Agreement dated April 15, 2026
• ·Convertible Promissory Note dated April 21, 2026
• ·Common Share Purchase Warrant dated April 15, 2026, with exercise price of $1.00 per share, exercisable until April 15, 2031
• ·Warrant shares allocated as 300,000 for first tranche and 300,000 for second tranche
• ·Advisory Agreement dated April 14, 2026

22-04-2026

Zoned Properties, Inc., through its subsidiaries, entered into a Real Estate Purchase and Sale Agreement on April 20, 2026, to sell three properties (Green Valley, Kingman, and Chino Valley) to Broken Arrow Herbal Center, Inc. for an aggregate $9.0 million. The purchase price allocation is $8.0 million for the Chino Property, $0.5 million each for Kingman and Green Valley Properties, payable via $4.0 million cash and a $5.0 million secured promissory note. Closing is scheduled for June 30, 2026, with Purchaser extension options to August 31 and September 30, 2026, for certain properties.

• ·Properties: (i) 1732 W. Commerce Point Place, Green Valley, AZ 85614; (ii) 2095 E. Northern Avenue, Kingman, AZ 86409; (iii) 2144-2148 N. Road 1 East, Chino Valley, AZ 86323.
• ·Purchaser exercising purchase options from existing lease agreements dated January 1, 2026.
• ·Closing extensions: Purchaser may extend to August 31, 2026 (Green Valley and Kingman close June 30 for $1.0M cash aggregate; Chino to August 31), and further to September 30, 2026 for Chino with $1.0M supplemental deposit.
• ·Properties sold 'as is, where is, with all faults'; Seller to remove certain monetary liens.
• ·Default remedies: Seller retains deposit as liquidated damages on Purchaser default; Purchaser may terminate and recover deposit (less $100) or seek specific performance on Seller default.

22-04-2026

Sky Quarry Inc. entered into an Amended and Restated Sales Agreement (A&R Sales Agreement) with Muriel Siebert & Co., LLC, replacing Cantor Fitzgerald & Co. as the sole sales agent for its at-the-market (ATM) equity offering program under a shelf registration statement. The A&R Sales Agreement maintains prior material terms, including a 3.0% commission to the agent, but updates the aggregate offering size for ATM Shares to $12,600,000 from the prior $4,700,000. No sales obligation exists, and the program can be suspended or terminated at the Company's discretion.

• ·Shelf registration statement on Form S-3 (File No. 333-291721) filed November 21, 2025, declared effective December 18, 2025.
• ·Common Stock trades under symbol SKYQ on Nasdaq Capital Market.
• ·Legal opinion on legality of ATM Shares issuance and sale provided by Winston & Strawn LLP (Exhibit 5.1).

22-04-2026

Blaize Holdings, Inc. adopted a limited duration stockholder rights plan, expiring April 21, 2027, in response to a specific threat from stockholders seeking to form a group that could gain control without compensating all shareholders. The plan triggers upon any entity, person, or group acquiring 10% or more beneficial ownership of common shares, entitling other holders to purchase shares at a 50% discount to market price or exchange rights for one share. Existing owners at or above 10% may retain shares but cannot acquire more without triggering the plan, ensuring fair treatment for all stockholders.

• ·Rights become void for the triggering person, entity, or group.
• ·Plan does not prevent Board-determined actions in the best interest of the Company and stockholders.
• ·Further details to be in a subsequent Form 8-K filing.

22-04-2026

Vivos Therapeutics, Inc. received a Nasdaq notice on April 17, 2026, indicating failure to meet the $2.5M minimum stockholders’ equity requirement under Listing Rule 5550(b)(1), with reported negative equity of approximately $1.55M as of December 31, 2025. The company raised $6.8M in aggregate gross proceeds during Q1 2026 via a $4.6M warrant exercise and $2.25M private placement to address the deficiency, but these do not fully cure it. The company has until June 1, 2026, to submit a compliance plan, with possible extension to October 14, 2026, though delisting remains a material risk if unsuccessful.

• ·No immediate impact on the listing or trading of VVOS common stock on Nasdaq
• ·Compliance plan submission deadline: June 1, 2026; potential extension through October 14, 2026
• ·Delisting would have a material adverse effect on the company, its operations, and reputation

22-04-2026

Greenwave Technology Solutions, Inc. received a Nasdaq notice on April 20, 2026, for non-compliance with Listing Rule 5250(c)(1) due to failure to file its Form 10-K for the fiscal year ended December 31, 2025. The company has 60 calendar days to submit a compliance plan, with potential extension up to 180 days until October 12, 2026, if accepted. While trading of GWAV common stock continues uninterrupted on the Nasdaq Capital Market, there is heightened risk of delisting if compliance is not regained.

• ·Notification disclosed in accordance with Nasdaq Listing Rule 5810(b).
• ·Press release issued on April 22, 2026, attached as Exhibit 99.1.
• ·Forward-looking statements highlight risks including no assurance of regaining compliance or avoiding delisting.

22-04-2026

XMax Inc. renewed the employment agreement with CEO Xiaohua Lu on April 21, 2026, for a one-year term subject to renewal. Under the agreement, Mr. Lu will receive an annual salary of $80,000 and is eligible for an annual cash bonus at the Board's discretion. No other changes to compensation or officer status were reported.

• ·Employment Agreement filed as Exhibit 10.1
• ·Agreement renewal dated April 21, 2026; 8-K filed April 22, 2026

22-04-2026

Firefly Neuroscience, Inc. consummated an additional closing under its March 8, 2026 Securities Purchase Agreement, issuing 5,333,333 Units to an accredited investor for $8,000,000 at $1.50 per Unit. The company entered into an Amended and Restated Lock-Up Agreement imposing a 30-day transfer restriction on Lock-Up Securities ending May 16, 2026, and extended the deadline to file a Registration Statement with the SEC to May 21, 2026. No declines or flat metrics were reported in this financing update.

• ·Lock-Up Period: April 16, 2026 to May 16, 2026 (30 days).
• ·Registration Statement filing deadline extended to May 21, 2026; effectiveness targeted within 45-90 days post-filing.
• ·Securities issued in private placement exempt under Section 4(a)(2) and Rule 506(b) of Securities Act.

22-04-2026

Perpetua Resources Corp. filed an 8-K on April 22, 2026, disclosing entry into Amendment No. 2 to the Engineering, Procurement, and Construction Management Services Agreement dated April 16, 2026, between its subsidiary Perpetua Resources Idaho, Inc. and Hatch Ltd. The amendment is attached as Exhibit 10.1 with portions redacted pursuant to Regulation S-K Item 601(b)(10)(iv) and schedules omitted per Item 601(b)(2). No financial terms or quantitative impacts are detailed in the filing.

• ·8-K Items: 1.01 (Entry into Material Definitive Agreement), 9.01 (Financial Statements and Exhibits)
• ·Exhibit 10.1 includes Cover Page Interactive Data File (Inline XBRL) as Exhibit 104

22-04-2026

Nexalin Technology, Inc. (NXL) announced entry into agreements with Lindus Health to advance its 160-participant, triple-blinded, sham-controlled pivotal clinical trial for the HALO™ Clarity device targeting moderate-to-severe insomnia, with enrollment expected to begin in Q2 2026 to support a planned De Novo FDA submission. The trial builds on prior peer-reviewed data showing significant improvements over sham. The global sleep tech devices market was $29.3 billion in 2025 and is projected to reach $153.7 billion by 2035.

• ·Nexalin Gen-2 15 milliamp neurostimulation device approved in China, Brazil, Oman, and Israel.
• ·Trial conducted in collaboration with Lindus Health for full-scope execution including regulatory submissions, patient identification, and biostatistics.

22-04-2026

Hepion Pharmaceuticals, Inc. entered into securities purchase agreements with accredited investors to sell 17,500,000 shares of common stock at $0.04 per share, raising gross proceeds of $700,000 in a private placement offering that closed on April 21, 2026. The shares were issued in reliance on exemptions from registration under Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D. This financing event provides the company with additional capital, with no reported declines or flat metrics.

• ·Common stock has par value of $0.0001 per share and trades under symbol HEPA on OTC QB.
• ·Agreements include customary representations, warranties, conditions to closing, indemnification, and termination provisions.

22-04-2026

Graf Global Corp. received a notice from NYSE American on April 16, 2026, stating non-compliance with Section 1007 of the NYSE American Company Guide due to failure to timely file its Annual Report on Form 10-K for the year ended December 31, 2025. The notice has no immediate effect on trading but risks delisting if not cured within the six-month period from the Annual Report's due date, with a possible additional six-month extension subject to NYSE American approval. The Company is working to file the report as soon as practicable.

• ·Form 12b-25 filed on April 1, 2026, disclosing need for additional time to file 10-K
• ·Previous 10-K for year ended December 31, 2024, filed on March 13, 2025
• ·Cure period: six months from Annual Report due date, with possible further six-month extension request
• ·Press release issued on April 22, 2026 (Exhibit 99.1)

22-04-2026

Casella Waste Systems, Inc. entered into Master Lease Agreement No. 68105 with The Huntington National Bank effective April 20, 2026, as Lessee for equipment described in future Schedules. The non-cancelable net lease requires unconditional rent payments by Lessee, who bears all risks, with no warranties from Lessor and security interest in the Collateral. No specific equipment details, rent amounts, or financial obligations are quantified in the agreement excerpt.

• ·Agreement filed as EX-10.1 in 8-K on April 22, 2026, covering Items 1.01 (Entry into Material Definitive Agreement), 2.03 (Creation of Direct Financial Obligation), and 9.01 (Financial Statements and Exhibits)
• ·Lease terms commence on Acceptance Date per Schedule; non-prepayable and non-terminable by Lessee
• ·Lessor grants security interest in all Collateral across Schedules

22-04-2026

ServiceNow reported Q1 2026 subscription revenues of $3,671 million, up 22% YoY (19% CC), beating the high end of guidance, with total revenues of $3,770 million also up 22% YoY; cRPO reached $12.64 billion (+22.5% YoY) and RPO $27.7 billion (+25% YoY). The company closed acquisitions of Armis and Veza to bolster security capabilities, repurchased 20.1 million shares, and raised FY2026 subscription revenue guidance to $15,735-$15,775 million (22-22.5% YoY), though noting ~75bp Q1 growth headwind from Middle East conflicts and near-term margin pressures from Armis integration.

• ·Q2 2026 subscription revenues guidance: $3,815-$3,820M (22.5% YoY, 21-21.5% CC); cRPO growth 19-19.5%.
• ·FY2026 subscription revenues guidance raised to $15,735-$15,775M (22-22.5% YoY, 20.5-21% CC).
• ·Q1 impacted by ~75 basis points headwind to subscription growth from delayed Middle East deals.
• ·Armis acquisition expected to add ~125bp to Q2/FY subscription growth but cause margin headwinds (e.g., 25bp sub gross margin, 200bp FCF margin FY2026).

22-04-2026

Apimeds Pharmaceuticals US, Inc. received a notice from NYSE Regulation on April 17, 2026, stating non-compliance with continued listing requirements under Section 1007 of the NYSE American Listed Company Manual due to failure to timely file its Form 10-K for the fiscal year ended December 31, 2025. The company has an initial six-month cure period from April 17, 2026, to file the 10-K and regain compliance, with a possible additional six-month extension; it expects to file by April 30, 2026, but provides no assurance of meeting this date. The common stock continues to trade under ticker APUS with a '.LF' late filing designation, but the trading halt initiated on April 2, 2026, remains in effect.

• ·Securities registered: Common Stock, par value $0.01 per share, ticker APUS on NYSE American LLC
• ·Emerging growth company: Yes
• ·Form 12b-25 filed with SEC on March 31, 2025, disclosing delay reasons related to financial statement preparation and audit completion
• ·Press release issued April 22, 2026 (Exhibit 99.1)

22-04-2026

BIO-key International, Inc. received a notice from Nasdaq on April 16, 2026, for non-compliance with Listing Rule 5250(c)(1) due to failure to timely file its Form 10-K for the fiscal year ended December 31, 2025. The notification has no immediate effect on the listing or trading of the company's common stock (BKYI) on the Nasdaq Capital Market. The company issued a press release on April 22, 2026, regarding the matter.

• ·Non-compliance with Nasdaq Listing Rule 5250(c)(1), requiring timely filing of periodic financial reports with the SEC
• ·Securities registered: Common Stock (BKYI) on Nasdaq Capital Market
• ·Company address: 101 Crawfords Corner Road Suite 4116, Holmdel, NJ 07733; Phone: (732) 359-1100

22-04-2026

Tevogen Bio Holdings Inc. received Nasdaq notices on April 16 and 17, 2026, for failing the $50 million minimum market value of listed securities (Rule 5450(b)(2)(A)) and $15 million minimum market value of publicly held shares (Rule 5450(b)(2&3)(C)) over 30 consecutive business days. The company has 180 calendar days to comply, until October 13, 2026 (MVLS) and October 14, 2026 (MVPHS), by achieving the thresholds for 10-20 consecutive business days. No immediate delisting effect, but the company may consider options like transferring to Nasdaq Capital Market with no assurance of success.

• ·Notifications based on review of prior 30 consecutive business days.
• ·Emerging growth company status confirmed.
• ·Principal executive offices: 15 Independence Boulevard, Suite #210, Warren, New Jersey 07059.

22-04-2026

The Charles Schwab Corporation filed a Certificate of Designations authorizing 15,000 shares of 6.100% Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock, Series L, each with a $100,000 liquidation preference. Dividends are fixed at 6.100% per annum until the First Reset Date of June 1, 2031, after which they reset to the Five-Year Treasury Rate plus 2.250% for subsequent Reset Periods, payable quarterly starting September 1, 2026 if declared. The stock is perpetual, non-cumulative, and ranks senior to common stock but on parity with other preferred stock, with restrictions on junior stock dividends and repurchases if Series L dividends are unpaid.

• ·Dividend Payment Dates: 1st day of March, June, September, and December, commencing September 1, 2026
• ·First Reset Date: June 1, 2031; subsequent Reset Dates every fifth anniversary
• ·Dividends are non-cumulative and payable only if declared by Board or Authorized Committee
• ·Callable at Corporation's option on or after First Reset Date at $100,000 per share plus declared unpaid dividends
• ·Regulatory Capital Treatment Event allows redemption if Tier 1 capital treatment is at risk

22-04-2026

Crisp Momentum Inc. (CRSF) entered into a Loan Settlement and Share Repurchase Agreement dated April 20, 2026, with Banji Step K.K. and Motoko Yorozu to fully settle a convertible loan originally provided in September 2025 with principal of USD $2,900,000. Previously, TaleOn app assets were transferred in partial satisfaction, but instead of the remaining Carpenstream Inc. equity interest and TopReels app assets, Banji will transfer 80,000,000 shares of CRSF common stock back to the company as treasury shares upon closing. The agreement discharges all loan obligations, including principal and accrued interest as of April 15, 2026 (Payoff Amount per Schedule 1), with no further payments required.

• ·Agreement effective date: April 20, 2026; Closing within 3 Business Days after conditions met, by Outside Date May 31, 2026.
• ·Loan Agreement dated September 16, 2025; amended by Term Sheet dated October 27, 2025.
• ·TaleOn Assets previously transferred via Asset Purchase Agreement dated November 14, 2025.
• ·Conditions to closing include Board approval, independent valuation confirming Transferred Assets >= Outstanding Loan Balance, audited financials, legal opinions, and regulatory approvals.

22-04-2026

EON Resources Inc. received a notice of noncompliance from NYSE American on April 16, 2026, for failing to timely file its Form 10-K for the year ended December 31, 2025, by the April 15, 2026 deadline, due to ongoing delays in financial reporting and close procedures. The company has an Initial Cure Period until October 15, 2026, to file the report and regain compliance, with no immediate effect on the listing of its Class A Common Stock (EONR) or redeemable warrants (EONR WS), though delisting proceedings could commence if unresolved. While the company expects to file within the cure period, no assurances are provided, highlighting significant compliance risks amid its operations of 20,000 Permian Basin acres with 750 wells producing over 1,000 barrels of oil per day.

• ·Form 12b-25 for late filing was submitted on April 1, 2026.
• ·Potential additional six-month cure period beyond October 15, 2026, at NYSE American's discretion.
• ·Grayburg-Jackson Field features stacked pay zones from 1,500-4,000 feet depth; South Justis Field from 5,000-7,000 feet.

22-04-2026

SunPower Inc. raised $41 million in Convertible Senior Secured Notes with a 10% coupon, non-callable until maturity on May 1, 2029, and a 45% conversion premium to the $1.13 closing price, resulting in 25,022,887 shares issuable at $1.6385 per share. Proceeds will fund working capital and repay $18.75 million in debt, complemented by $21.25 million in 7.0% notes exchanged for stock and $10 million of Sunder M&A debt converted into the new notes, achieving a total $40 million debt reduction. CEO Rodgers personally invested $6 million, and Sunder's management team invested $10 million via debt conversion.

• ·Notes offered only to qualified institutional buyers or accredited investors; securities not registered under Securities Act.
• ·Market closing price used for premium: $1.13; conversion price: $1.6385.
• ·Press release dated April 21, 2026; filing dated April 22, 2026; closing expected this week.

22-04-2026

La Rosa Holdings Corp. (LRHC) received a Nasdaq notice on April 16, 2026, stating non-compliance with Listing Rule 5250(c)(1) due to failure to file its Form 10-K for the fiscal year ended December 31, 2025. The company has 60 days (until June 15, 2026) to submit a compliance plan, with potential extension up to 180 days (October 12, 2026), but faces delisting risk if unresolved, with no immediate impact on its Nasdaq listing. The company intends to file the 10-K promptly but provides no assurances of success.

• ·Nasdaq will consider the company's past compliance history, reasons for late filing, financial condition, and public disclosures when reviewing any compliance plan.
• ·Company operates a full-service escrow settlement and title company in Florida.
• ·Expansion into Europe has begun with Spain.

22-04-2026

Cue Biopharma, Inc. filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation, authorizing a one-for-thirty reverse stock split of its Common Stock effective at 5:00 p.m. Eastern Time on April 23, 2026. The amendment sets total authorized shares at 310,000,000, comprising 10,000,000 shares of Preferred Stock and 300,000,000 shares of Common Stock, both with a par value of $0.001 per share. No fractional shares will be issued; eligible stockholders will receive cash in lieu based on the closing price preceding the effective time multiplied by the reverse split number of 30.

• ·Reverse stock split ratio: every 30 shares of Common Stock reclassified into 1 share.
• ·Certificate executed on April 22, 2026, pursuant to Section 242 of Delaware General Corporation Law.
• ·Stock certificates or book entries automatically adjusted; new book entry positions issued upon surrender of old certificates.

22-04-2026

On April 16-17, 2026, Volato Group, Inc. entered into Share Exchange Agreements with shareholders of M2i Global, Inc., issuing 5,407,499 shares of Class A common stock in exchange for 48,044,912 shares of M2i Global common stock, with implied values of $0.0304 per M2i share and $0.2701 per Volato share. The transaction was conducted with accredited investors under exemptions from Securities Act registration, and Volato agreed to file a resale registration statement within 60 days. No financial performance metrics or period-over-period comparisons were disclosed.

• ·Agreements contain customary representations, warranties, and obligations.
• ·Volato shares issued in reliance on Section 4(a)(2) of the Securities Act and Regulation D.
• ·M2i Global common stock trades on OTCQB under symbol 'MTWO'.

22-04-2026

Maison Solutions Inc. filed a corrected Certificate of Amendment to its Amended and Restated Certificate of Incorporation on April 22, 2026, addressing an administrative error in the original March 23, 2026 filing by specifying an effective date of 12:01 a.m. Eastern time on April 24, 2026. The amendment implements a 1-for-10 reverse stock split of Class A common stock (par value $0.0001 per share), reclassifying every 10 shares of Old Common Stock into 1 share of New Common Stock, with fractional shares rounded up to the next whole share. The change was approved by the Board of Directors and stockholder written consent pursuant to Delaware law.

• ·Original Certificate of Amendment filed with Delaware Secretary of State on March 23, 2026.
• ·Corrected certificate signed on April 15, 2026.
• ·No change to par value ($0.0001 per share) or stated capital/paid-in surplus.

22-04-2026

BMW Vehicle Lease Trust 2026-1 closed the issuance of asset-backed notes on April 22, 2026, with Class A-1 at $249,600,000 (3.830%), Class A-2a at $490,200,000 (4.03%), Class A-2b at $90,000,000 (Benchmark + 0.37%), Class A-3 at $580,200,000 (4.15%), and Class A-4 at $90,000,000 (4.18%), totaling $1,500,000,000 secured by a SUBI Certificate in BMW vehicle leases and related vehicles. The transaction involved multiple agreements including the Indenture with U.S. Bank Trust Company, National Association, 2026-1 Vehicle Trust Supplement, Servicing Supplement, and transfer agreements among BMW Manufacturing L.P., BMW Auto Leasing LLC, and the Trust. No performance metrics or prior period comparisons are provided in the filing.

• ·Underwriting Agreement dated April 14, 2026, with J.P. Morgan Securities LLC as representative of underwriters.
• ·Depositor Certification dated April 14, 2026, for shelf offerings of asset-backed securities (previously filed April 16, 2026).